BACKGROUND: Flu vaccination in otherwise healthy infants and young children is important to prevent severe disease, as well as to control epidemic spread of influenza infection. AIMS: To examine the safety and immunogenicity of a paediatric presentation of a purified, inactivated, triton split influenza vaccine. METHODS: Two doses of the vaccine, provided in prefilled syringes of 0.25 ml, were administered, one month apart, to 67 children under 3 years of age. RESULTS: Nine cases of immediate reaction to vaccination (macules/papules) were observed after the second injection only. During the study period, 9% of children experienced at least one delayed local reaction, and 28% of children presented at least one systemic reaction. Almost all reactions were mild and transient. Immunogenicity results surpassed the European Community recommendations for a 0.50 ml dose of vaccine in adults. CONCLUSION: This paediatric formulation of inactivated flu vaccine appears safe and immunogenic in children from 6 months to 3 years of age; the convenient presentation in a prefilled syringe of 0.25 ml volume will facilitate administration of the dose recommended for young children.
BACKGROUND: Flu vaccination in otherwise healthy infants and young children is important to prevent severe disease, as well as to control epidemic spread of influenza infection. AIMS: To examine the safety and immunogenicity of a paediatric presentation of a purified, inactivated, triton split influenza vaccine. METHODS: Two doses of the vaccine, provided in prefilled syringes of 0.25 ml, were administered, one month apart, to 67 children under 3 years of age. RESULTS: Nine cases of immediate reaction to vaccination (macules/papules) were observed after the second injection only. During the study period, 9% of children experienced at least one delayed local reaction, and 28% of children presented at least one systemic reaction. Almost all reactions were mild and transient. Immunogenicity results surpassed the European Community recommendations for a 0.50 ml dose of vaccine in adults. CONCLUSION: This paediatric formulation of inactivated flu vaccine appears safe and immunogenic in children from 6 months to 3 years of age; the convenient presentation in a prefilled syringe of 0.25 ml volume will facilitate administration of the dose recommended for young children.
Authors: H S Izurieta; W W Thompson; P Kramarz; D K Shay; R L Davis; F DeStefano; S Black; H Shinefield; K Fukuda Journal: N Engl J Med Date: 2000-01-27 Impact factor: 91.245
Authors: D W Teele; J O Klein; B Rosner; L Bratton; G R Fisch; O R Mathieu; P J Porter; S G Starobin; L D Tarlin; R P Younes Journal: JAMA Date: 1983-02-25 Impact factor: 56.272
Authors: P G Steinherz; A E Brown; P A Gross; D Braun; F Ghavimi; N Wollner; G Rosen; D Armstrong; D R Miller Journal: Cancer Date: 1980-02-15 Impact factor: 6.860
Authors: O Ruuskanen; M Arola; A Putto-Laurila; J Mertsola; O Meurman; M K Viljanen; P Halonen Journal: Pediatr Infect Dis J Date: 1989-02 Impact factor: 2.129
Authors: E Young Bae; Ui Yoon Choi; Hyo Jin Kwon; Dae Chul Jeong; Jung Woo Rhim; Sang Hyuk Ma; Kyung Il Lee; Jin Han Kang Journal: Clin Vaccine Immunol Date: 2013-03-27